Northern Trust
MPLT

Northern Trust’s MapLight Therapeutics MPLT Stock Holding History

Northern Trust’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.18M Sell
116,652
-29,520
-20% -$849K ﹤0.01% 2717
2026
Q1 		$2.97M Buy
146,172
+26,615
+22% +$476K ﹤0.01% 2750
2025
Q4 		$2.1M Buy
+119,557
New +$2M ﹤0.01% 2972

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Northern Trust's MPLT Position: Q2 2026 in Review

Northern Trust reduced its MapLight Therapeutics (MPLT) stake by 20% in Q2 2026, selling an estimated $849K and leaving 116,652 shares worth $4.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2717.

Northern Trust first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Northern Trust held 116,652 shares of MapLight Therapeutics worth $4.18M as of Q2 2026.
  • Northern Trust sold 29,520 MapLight Therapeutics shares in Q2 2026, an estimated $849K.
  • MapLight Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2717 holding.
  • Northern Trust first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.